Meeting
2018 Gastrointestinal Cancers Symposium
Preclinical study of antitumor activity of trastuzumab emtansine in HER2-positive biliary tract cancer.
Authors
Yoriko Yamashita-Kashima
Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
Yoriko Yamashita-Kashima , Takaaki Fujimura , Sei Shu , Mieko Yanagisawa , Marie Mochizuki , Keigo Yorozu , Mirei Kouno , Koh Furugaki , Ryota Higuchi , Junichi Shoda , Naoki Harada , Yasushi Yoshimura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 256)
DOI
10.1200/JCO.2018.36.4_suppl.256
Abstract #
256
Poster Bd #
C9
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
First Author: Funda Meric-Bernstam
Poster
2024 ASCO Annual Meeting
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).
First Author: Do-Youn Oh
Poster
2022 ASCO Annual Meeting
Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).
First Author: Choong-kun Lee
Poster
2021 ASCO Annual Meeting
A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).
First Author: Choong-kun Lee